📇 Rhumatologue · MONTMIRAIL · (51) · Libéral
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Référence presse grand public
Cité 1 fois dans les médias — pédagogie reconnue
Expérience confirmée
37 ans d'exercice en rhumatologie — recul clinique solide
Délais de RDV courts dans la région
134.8 rhumatos / 100 000 hab. — département bien doté
37ans d'exercice (thèse 1989)
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.
CABINET DU DR SYLVIO MAZZA
13 RUE DE MONTLEAN, 51210 MONTMIRAIL
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
📰 Actu.fr · 09/07/2013
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxPMnNqX1lvbGthSTVfSmViTWFjMlAzdlNxVlUtWVJNWUlqbElrR2lrOFZCQXpjSTJLYURzd01vU1J0czhaT0ZBS08zenllaWhubEJQTkxWR1FKTDJGdFJ0Q01EeWNTelRRdWdMb0x0WlV4RFJjSFdMUVpQNVh4VmxZR3lzeS1tazZUZUd5TDhaSEtYbzljR2k0bE5vS2lxRDdhUm15bnRkYTFPOEo0SmVKdw?oc=5" targe
Lupus · 2020
Introduction Assessment of risk both for pregnancy morbidity and thrombosis in the presence of anti-phospholipid antibodies (aPL) is still a challenge in Systemic Lupus Erythematosus (SLE) patients. The Global Antiphospholipid Syndrome Score (GAPSS) takes into account the aPL profile (criteria and non-criteria aPL), the conventional cardiovascular risk factors and the autoimmune antibody profile. An adjusted model of the score (aGAPSS) excluding anti-phosphatidylserine/Prothrombin (aPS/PT), suggests that the score is able to stratify patients for their rate of events making it widely applicable in daily clinical practice. Objective To validate the aGAPSS in a multicentric cohort of SLE patients in Argentina. Patients and methods consecutive SLE patients with and with andwithout thrombotic events from seven Rheumatologist centers were included. Traditional cardiovascular risk factors, aPL antibodies and medications received (aspirin, hydroxychloroquine and anticoagulation) were collected. The score aGAPSS was calculated for each patient at the last visit by adding together the points corresponding to the risk factors: 1 for hypertension, 3 for dyslipidemia, 4 for LA and B2GPI (IgM or IgG) antibodies and 5 for aCL (IgM or IgG) antibodies. The discriminative ability of the aGAPSS was calculated by measuring the area under the receiver operating characteristic curve (AUC). Multivariate logistic regression analysis was performed to examine the impact of multiple cardiovascular risk factors and laboratory parameters on the occurrence of thrombosis. Results Two hundred and ninety-six SLE patients were included. One-hundred and twenty-one patients (40.9%) presented thrombotic and/or pregnancy complications. Median aGAPSS was significantly higher in patients who experienced an event (thrombosis and/or pregnancy morbidity) compared with those without [4 (IQR 1–9) versus 1 (IQR 0–5); p < 0.001]. The best cut off point for the diagnosis of thrombosis and/or pregnancy complications was aGAPSS ≥4. Multivariate logistic regression analysis showed that aCL antibodies [OR 2.1 (95% CI 1.16–3.90); p = 0.015] were an independent risk factors for thrombotic events. Conclusions This score is a simple tool, easy to apply to SLE patients in daily practice. The use of the aGAPSS could change the non-pharmacologic and pharmacologic treatment in higher risk patients to improve their survival.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Lupus · 2020 · Journal Article
Garcia L, Velloso MS, Martire MV, Savy F, et al.
Lupus · 2020 · Journal Article
Garcia L, Velloso MS, Martire MV, Savy F, et al.